AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17264714
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg daily dexibuprofen
Trial: 15891954
Drug: Pramlintide +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramlintide + insulin
Trial: 15891954
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + insulin
Trial: 11976561
Drug: Metformin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treatment after one month
Trial: 9670263
Drug: Intraarterial hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial hepatic chemotherapy (IAHC) using IA FUDR
Trial: 9670263
Drug: Intraarterial hepatic
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial hepatic chemotherapy (IAHC)
Trial: 9670263
Drug: New protocols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New protocols and combinations with systemic chemotherapy
Trial: 7614642
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg.kg‐1)
Trial: 1854047
Drug: Thiopentone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4 mg.kg‐1)
Trial: 484813
Drug: Methohexitone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 0.5 mg/kg
Trial: 484813
Drug: Etomidate 0.067
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.067 mg/kg
Trial: 11136909
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group 3
Trial: 30682557
Drug: Severity of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severity of alcohol and drug use problems
Trial: 29061010
Drug: Remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 μg·kg(‐1)·min(‐1) (Group S)
Trial: 29061010
Drug: Remifentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.3 μg·kg(‐1)·min(‐1) (Group L)
Trial: 29061010
Drug: Remifentanil 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.3 μg·kg(‐1)·min(‐1) + lappaconitine 8 mg (Group G)
Trial: 24499494
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg NRL001 (2 g suppository)
Trial: 9085171
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of UST and PDN
Trial: 8519040
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (ECA) 325 mg/day
Trial: 8519040
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin (BA) 325 mg/day
Trial: 8519040
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin (ASA) 325 mg/day
Trial: 7306432
Drug: Imipramine 100
RxNorm normalized name: trimipramine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 100 mg
Trial: 31752595
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment for insomnia (CBT-I)
Trial: 29420925
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of HMB-FA
Trial: 18764978
Drug: Controlled-release levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa (CR-LD)
Trial: 18764978
Drug: Immediate-release levodopa
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Immediate-release levodopa (IR-LD)
Trial: 24859356
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated Heparin
Trial: 2665657
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b conjugate vaccine (standard dose)
Trial: 2665657
Drug: Haemophilus influenzae
RxNorm normalized name: HAEMOPHILUS INFLUENZAE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus influenzae type b conjugate vaccine (low dose)
Trial: 2665657
Drug: Diphtheria, pertussis,
RxNorm normalized name: diphtheria, pertussis, tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria, pertussis, and tetanus and polio vaccines only (Control)
Trial: 30357310
Drug: Tailored, dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored, dose-dense (DD) epirubicin/cyclophosphamide (E/C) and tailored docetaxel (D) (tDD)
Trial: 25814042
Drug: Tobramycin aerosol
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin aerosol (150mg/3ml) administered via the Easynose® device
Trial: 20168104
Drug: Moxibustion (stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion (stimulating acupoint BL 67 daily for 2 weeks)
Trial: 15998172
Drug: Fluticasone/salmeterol combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/salmeterol combination
Trial: 9447537
Drug: Topical lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lidocaine and prilocaine cream (1 to 1.25 gm)
Trial: 2847676
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at high pressor dose (to increase diastolic pressure by 25 mmHg) in healthy volunteers
Trial: 2847676
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in healthy subjects
Trial: 2847676
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion at low pressor dose (to increase diastolic pressure by 12-15 mmHg) in patients with mild essential hypertension
Trial: 30433852
Drug: Fluorouracil plus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plus cisplatin and radiation twice a day (FCT)
Trial: 30433852
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily radiation plus gemcitabine (GD)
Trial: 11565624
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg on days 1-7, 100 mg on days 8-14)
Trial: 11565624
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg on days 1-7, 40 mg on days 8-14)
Trial: 9630155
Drug: Single transperineal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single transperineal injection of botulinum toxin
Trial: 7943829
Drug: ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 0.15 mg.kg-1
Trial: 7943829
Drug: metoclopramide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoclopramide 0.5 mg.kg-1
Trial: 7943829
Drug: droperidol 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 0.075 mg.kg-1
Trial: 26431470
Drug: AFN-1252 200
RxNorm normalized name: AFN-1252
DrugBank: AFN-1252 (DB12658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFN-1252 200 mg single dose in fed versus fasted subjects
Trial: 26431470
Drug: AFN-1252 200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFN-1252 200, 300, and 400 mg doses administered once-daily for 10 days
Trial: 26431470
Drug: AFN-1252 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFN-1252 (all doses)
Trial: 16430413
Drug: Morphine gel
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine gel (0.2 mg.kg(‐1), 1 mg.ml(‐1))
Trial: 16430413
Drug: Morphine solution
RxNorm normalized name: morphine Injectable Solution
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine solution in saline (0.2 mg.kg(‐1), 1 mg.ml(‐1))
Trial: 11107681
Drug: Glycoprotein IIb‐IIIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb‐IIIa receptor inhibitors
Trial: 3862608
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - 600 mg/day
Trial: 3862608
Drug: Ambroxol (AMB)
RxNorm normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (AMB) - 90 mg/day
Trial: 26774901
Drug: Intra-articular autologous
RxNorm normalized name: autologous cultured chondrocytes 1.2e+007 INTRA-ARTICULAR IMPLANT [CARTICEL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular autologous PRP injection
Trial: 20056436
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 μg/kg bolus followed by a 0.5 μg/kg/min infusion for 30 minutes after induction but before sternotomy)
Trial: 16507189
Drug: Inhalation induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation induction with sevoflurane
Trial: 12846706
Drug: Intravenous induction
RxNorm normalized name: Intravenous induction agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous induction with thiopental
Trial: 11764112
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group 2) - SEM examination without further treatment
Trial: 8804878
Drug: Acetorphan (100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetorphan (100-300 mg thrice daily)
Trial: 8804878
Drug: Octreotide (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50-150 micrograms thrice daily)
Trial: 6698743
Drug: Topical imipramine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imipramine 0.05%
Trial: 30193579
Drug: Prophylactic subcutaneous
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic subcutaneous scopolaminebutyl
Trial: 22129855
Drug: Ayurvedic zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic zinc (Jasad) tablets
Trial: 19766734
Drug: Counselor initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Counselor initiated tobacco quit line with 6 scheduled telephone sessions and 8 weeks of nicotine replacement therapy (NRT)
Trial: 19766734
Drug: Participant initiated
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participant initiated tobacco quit line with 6 scheduled telephone sessions and 2 weeks of nicotine replacement therapy (NRT)
Trial: 17344030
Drug: Hypericum extract
RxNorm normalized name: Hypericum extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum extract (W55570) 300 mg t.i.d
Trial: 9574879
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg, once daily for 7 days
Trial: 30055591
Drug: Care and
RxNorm normalized name: ALCOHOL 0.65 mL in 1 mL TOPICAL GEL [Scentia Pro Care and Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Care and treatment services for PLHIV
Trial: 16984503
Drug: MMX mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine 2.4 g/day
Trial: 16984503
Drug: MMX mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine 4.8 g/day
Trial: 17882140
Drug: Caffeine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (50 mg)
Trial: 10702430
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (4 ppm)
Trial: 10702430
Drug: Prostaglandin E(1)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E(1) infusion (8 ng/kg/min)
Trial: 7682395
Drug: Hyperthermo-chemotherapy (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermo-chemotherapy (Group B)
Trial: 7682395
Drug: Chemotherapy (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Group A)
Trial: 6135690
Drug: Clobazam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (mean daily dose: 59 mg)
Trial: 6135690
Drug: Diazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (mean daily dose: 25 mg)
Trial: 29303067
Drug: Modified tumescent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified tumescent solution (gas‐liquid mixing tumescent solution)
Trial: 29303067
Drug: Traditional tumescent
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional tumescent solution
Trial: 9010687
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin
Trial: 28962668
Drug: Tapering/discontinuation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering/discontinuation of antipsychotic medication using a smartphone application to monitor early warning signs of psychotic relapse
Trial: 28962668
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with antipsychotic medication
Trial: 28962668
Drug: Tapering/discontinuation of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering/discontinuation of antipsychotic medication
Trial: 28962668
Drug: Tapering/discontinuation and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapering/discontinuation and maintenance therapy
Trial: 18543484
Drug: Airening Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Airening Suppository (ARN)
Trial: 16641323
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) adjunctive therapy at a target dose of 60 mg/kg/day
Trial: 16641323
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) adjunctive therapy
Trial: 14584069
Drug: Isocaloric low-fat/high-fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric low-fat/high-fiber diet (20% calories as fat, 25 g/day fiber, at least 8 servings of fruits/vegetables per day)
Trial: 1740678
Drug: rhGM‐CSF (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF (subcutaneous or intravenous administration)
Trial: 31784702
Drug: topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical tacrolimus 0.1%
Trial: 31784702
Drug: topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cyclosporine 1%
Trial: 28411246
Drug: GDF‐15 measured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDF‐15 measured at 1 month after ACS (elevated GDF‐15 >1800 ng/L)
Trial: 22230187
Drug: Part C
RxNorm normalized name: diluent,insulin aspart combination no.1 INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part C early intervention (EI) therapy
Trial: 22230187
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (matched with EI therapy group)
Trial: 11169930
Drug: Exemestane (EXE)
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane (EXE) 25 mg per day
Trial: 10209938
Drug: Arginine infusion
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arginine infusion (20 g over 2 hours)
Trial: 3252755
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg single oral dose
Trial: 30218514
Drug: Premature Infant
RxNorm normalized name: Premature infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature Infant Oral Motor Intervention (structured stimulation)
Trial: 29507779
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) with 100 mg aspirin daily
Trial: 29507779
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg aspirin daily (Control)
Trial: 23591306
Drug: I-gel and
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-gel and Endotracheal intubation
Trial: 21072235
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose rifampicin (SDR)
Trial: 21072235
Drug: Standard multidrug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard multidrug therapy (MDT) program with additional chemoprophylaxis
Trial: 18946448
Drug: Short wave
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short wave diathermy (SWD) and non-steroidal anti-inflammatory drugs (NSAID)
Trial: 17184455
Drug: 2% glacial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% glacial acetic acid, 0.1% dexamethasone and 3250 U/ml of neomycin sulphate
Trial: 14740951
Drug: DENV candidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV candidate vaccines
Trial: 14740951
Drug: DENV-1, DENV-2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-1, DENV-2, DENV-3 candidate vaccines
Trial: 14740951
Drug: DENV-2, DENV-3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DENV-2, DENV-3, DENV-4 vaccine candidates
Trial: 10952481
Drug: Benfotiamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine (100 mg)
Trial: 10952481
Drug: Thiamine nitrate
RxNorm normalized name: Thiamine nitrate
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamine nitrate (100 mg)
Trial: 9278568
Drug: Beta-carotene (0.11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (0.11 mmol / 60 mg)
Trial: 9278568
Drug: Combined dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dose of beta-carotene and lycopene (0.11 mmol each)
Trial: 31648564
Drug: Prednisone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (5 mg/kg) for 4 weeks
Trial: 31648564
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg/kg) for 4 weeks
Trial: 31648564
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of prednisone (20 mg for 5 days)
Trial: 31648564
Drug: Increasing concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing concentrations (0-200 ng/mL) of prednisone or prednisolone
Trial: 31648564
Drug: GC-receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GC-receptor antagonist (RU486)
Trial: 23520150
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH; tinzaparin)
Trial: 23520150
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (tinzaparin plus warfarin for ≥12 weeks at home)
Trial: 21538451
Drug: Generic drug
RxNorm normalized name: CELECOXIB 200 mg ORAL CAPSULE [Generic drug]
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic drug
Trial: 21538451
Drug: Standard drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard drug
Trial: 17823445
Drug: Soybean isoflavones
RxNorm normalized name: Soybean isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean isoflavones with inulin (3.66 g)
Trial: 15282384
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate (FP; 250 microg twice daily) for 2 weeks
Trial: 9602688
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg for 30 to 40 days (mean 35)
Trial: 9602688
Drug: Azithromycin 1000
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1000 mg for 21 to 50 days (mean 37)
Trial: 9602688
Drug: Azithromycin 1500
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1500 mg for 20 days
Trial: 9602688
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose maintenance treatment with azithromycin for 30 to 360 days (mean 129)
Trial: 9602688
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term initial course of azithromycin (various doses)
Trial: 7684157
Drug: Doxazosin 4
RxNorm normalized name: doxazosin 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 4 mg once daily
Trial: 2711711
Drug: Non‐medicamentous therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐medicamentous therapy (CNT)
Trial: 2711711
Drug: Medicamentous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicamentous therapy
Trial: 14253279
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at 12.5, 25.0, 37.5, and 50.0 mg/kg